Results from Mont Blanc Phase 3 Trial of Nicox’s NCX 470 in Glaucoma Published

Nicox has published results results from the Mont Blanc phase 3 trial comparing NCX 470 to latanoprost in the lowering of IOP in patients with open-angle glaucoma or ocular hypertension in the American Journal of Ophthalmology. 

“We are pleased to see the publication of these data in such a recognized and respected journal,” said Doug Hubatsch, Chief Scientific Officer of Nicox. “The data from the Mont Blanc phase 3 trial demonstrated the potential of NCX 470 and we look forward to seeing confirmation of this clinical profile in the upcoming results from the ongoing Denali phase 3 trial, expected in H2 2025. I’d also like to thank all the Mont Blanc study sites for their excellent work on this trial.”

The publication entitled “A Randomized, Controlled Comparison of NCX 470, a Nitric Oxide-Donating Bimatoprost, and Latanoprost in Subjects with Open-Angle Glaucoma or Ocular Hypertension: The MONT BLANC Study” was published online in the American Journal of Ophthalmology on March 16, 2024 and is available by clicking here.

The Mont Blanc publication concludes that “The NO-donating prostaglandin analogue NCX 470 0.1% was well-tolerated and lowered IOP more than latanoprost in subjects with open-angle glaucoma or ocular hypertension at all 6 time points. With a dual mechanism of action that enhances both uveoscleral and trabecular outflow, NCX 470 could become an important first-line therapy for IOP reduction in glaucoma.”